The Dow Jones Industrial Average
Let's focus on two biotechs that made moves because of breaking news.
Investors also need to set reasonable expectations for what a positive approval means. As fellow Fool Brian Orelli points out, pixantrone is a third-line treatment, so the type of blockbuster enthusiasm that sent Dendreon
And at the opposite end of the spectrum we have SIGA Technologies
The two companies' relationship would fall under the "it's complicated" status on Facebook after SIGA canceled a merger with PharmAthene once it realized how valuable smallpox antiviral drug ST-246 was. PharmAthene recently won a court verdict affirming its right to a portion of the drug's profits. Although the legal wrangling could continue, today's pop is still excellent news for both companies, and investors should be able to relax and enjoy the weekend.
The best way to track the latest developments surrounding the aforementioned companies is to add them to our free My Watchlist feature:
- Add Adeona Pharmaceuticals to My Watchlist.
- Add Cell Therapeutics to My Watchlist.
- Add Dendreon to My Watchlist.
- Add Spectrum Pharmaceuticals to My Watchlist.
- Add SIGA Technologies to My Watchlist.
- Add PharmAthene to My Watchlist.
Want to know what company our analysts think is so poised for monster returns they named it The Motley Fool's Top Stock for 2012? Download this special free report before the market wakes up and realizes this amazing investment opportunity.